Eculizumab | AETNA Coverage Update

Summary: Aetna, a CVS Health company, modified CPB 0807 governing eculizumab coverage policy, effective April 2, 2026. Here's what billing teams need to know before submitting claims.

Eculizumab is one of the most expensive drugs in modern medicine — a single year of treatment can exceed $500,000. That makes Aetna's update to CPB 0807 eculizumab billing guidelines a high-stakes change for any specialty practice or infusion center billing these claims. The policy does not list specific CPT or HCPCS codes in the available data, so your team needs to verify applicable codes directly against the full policy document before the effective date of April 2, 2026.

Quick-Reference Table

Aetna Eculizumab Coverage Criteria and Medical Necessity Requirements 2026

Eculizumab (brand name Soliris) is a complement inhibitor approved for several rare, serious conditions. Because of its cost, payers like Aetna apply strict medical necessity criteria and prior authorization requirements before they'll pay a claim. That's exactly why a modification to CPB 0807 in the Aetna system matters — even a small wording shift in a coverage policy at this price point translates directly to claim denials or approvals worth hundreds of thousands of dollars.

The CPB 0807 Aetna coverage policy historically covers eculizumab for a defined set of FDA-approved indications. These include paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). Each indication carries its own medical necessity criteria, and Aetna typically requires documentation showing the member meets specific diagnostic, laboratory, and treatment history thresholds before authorizing coverage.

Prior authorization is required for eculizumab under Aetna plans. That's not new — but modifications to the coverage policy often shift what documentation satisfies prior auth. If the April 2, 2026 update tightened the criteria for any specific indication, authorizations you secured under the old criteria may not be sufficient for ongoing or new claims. Pull your active auth files and compare them against the updated policy now.

The real issue with eculizumab billing is that medical necessity denials are common even when the drug is clinically appropriate. Aetna's prior auth reviewers look for specific laboratory values, prior treatment failures, and specialist attestation. If your documentation doesn't hit every checkbox in the updated CPB 0807 criteria, expect a denial — not a request for additional information.

Because the available policy data does not include the specific criteria language that changed, your next step is to pull the full policy from the Aetna provider portal or directly at the source. Read the old version against the new one. If you don't have version comparison tools, your billing consultant or compliance officer needs to do this manually before April 2, 2026.

Aetna Eculizumab Exclusions and Non-Covered Indications

Eculizumab has a narrow approved indication set, and Aetna's CPB 0807 has historically treated off-label use as experimental or investigational. That matters because eculizumab is sometimes used in clinical practice for conditions beyond its FDA-approved label — conditions like kidney transplant rejection, HELLP syndrome, or other complement-mediated disorders.

Aetna's coverage policy typically designates off-label eculizumab use as not medically necessary unless supported by published, peer-reviewed clinical evidence that meets the payer's evidentiary standard. That's a high bar. Don't assume that a physician's letter of medical necessity alone will flip an experimental designation.

The modification to CPB 0807 may have added or removed indications from the experimental list. Without the full policy text, it's impossible to confirm which indications moved. If your practice uses eculizumab for any condition beyond PNH, aHUS, gMG, or NMOSD, treat this policy change as a direct flag to re-verify coverage status before April 2, 2026.

Coverage Indications at a Glance

The available policy data does not include indication-level coverage details from the modified CPB 0807 text. The table below reflects the established coverage framework for eculizumab under Aetna policy — verify every row against the updated full policy document before billing.

Verify this table against the updated CPB 0807 policy. Do not bill based on this summary alone.

Aetna Eculizumab Billing Guidelines and Action Items 2026

Here's what your billing team and prior auth staff need to do before claims dated April 2, 2026 go out the door.

CPT, HCPCS, and ICD-10 Codes for Eculizumab Under CPB 0807

The available policy data for CPB 0807 does not list specific CPT, HCPCS, or ICD-10 codes. Do not infer or substitute codes based on this post alone.

That said, eculizumab billing typically involves HCPCS codes for the drug itself and infusion administration codes. Your team should verify the exact codes Aetna recognizes under the updated CPB 0807 directly through the Aetna provider portal or by contacting your Aetna provider relations representative.

When you pull the full policy, look for:

• The HCPCS J-code assigned to eculizumab (Soliris)
• Any infusion administration codes Aetna pairs with coverage
• ICD-10-CM diagnosis codes that satisfy the covered indication criteria for each approved condition

Until you confirm those codes from the actual CPB 0807 document, do not update your charge capture. Billing the wrong code pairing — even with correct clinical documentation — produces a claim denial that takes time and resources to fix. Get the codes from the source.